SEER data show that small cell lung cancer (SCLS) incidence has steadily declined due to reduced smoking rates, but survival outcomes have seen only minimal improvement, underscoring the need for ...

Once non-small-cell lung cancer (NSCLC) spreads far and wide ... like your brain or adrenal gland, you might have surgery to remove the tumor. Sometimes, the first therapy you try doesn't work ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

Imdelltra is associated with improvement in overall survival compared to local standard-of-care chemotherapy among patients with small cell lung cancer.

In a small study, lactotransferrin (LTF) was identified as a potentially important biomarker in extensive-stage small cell ...

A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due ...

A new study published in The Annals of Thoracic Surgery suggests that Medicaid expansion under the Affordable Care Act has ...

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...

New research shows that Medicaid expansion was linked to a 2.1% increase in timely lung cancer surgeries and a 2.8% rise in ...

Lung cancer is the number one cancer killer in the world. Biomarker testing improves outcomes in stage IV non-small cell lung cancer (NSCLC), however its ...

EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...

Small-cell lung cancer (SCLC) is the most aggressive type of lung cancer. Each year in the U.S., about 30,000 to 35,000 people are diagnosed with it. For most, it has already spread to distant ...